Show simple item record

dc.contributor.authorSewak, S
dc.contributor.authorKosmider, S
dc.contributor.authorGanju, V
dc.contributor.authorWoollett, A
dc.contributor.authorYeow, EG
dc.contributor.authorLe, B
dc.contributor.authorHenry, M
dc.contributor.authorDebrincat, MA
dc.contributor.authorBell, R
dc.date.available2014-05-21T22:00:15Z
dc.date.issued2010-03-01
dc.identifierpii: IMJ1987
dc.identifier.citationSewak, S., Kosmider, S., Ganju, V., Woollett, A., Yeow, E. G., Le, B., Henry, M., Debrincat, M. A. & Bell, R. (2010). Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting. INTERNAL MEDICINE JOURNAL, 40 (3), pp.201-208. https://doi.org/10.1111/j.1445-5994.2009.01987.x.
dc.identifier.issn1444-0903
dc.identifier.urihttp://hdl.handle.net/11343/28748
dc.descriptionC1 - Journal Articles Refereed
dc.description.abstractBACKGROUND: Androgen ablation is the standard treatment for advanced prostate cancer. However, most patients will eventually develop progressive hormone-refractory prostate cancer (HRPC). The aim of the Pacl-Vin study was to determine the efficacy and safety of paclitaxel in combination with vinorelbine in patients with HRPC, following from a phase I trial. METHODS: Thirty castrate patients with progressive, metastatic prostate cancer were enrolled. Patients were treated with paclitaxel 40 mg/m2, vinorelbine 20 mg/m2 intravenously on day 1 and day 8 of a 21-day cycle. RESULTS: Two patients demonstrated a partial response and seven patients had stable disease from a cohort of 10 patients with measurable disease. Of 30 patients assessable for prostate-specific antigen (PSA) response, 19 showed stable disease, which was maintained for at least 4 weeks, while six (20%) experienced>or=50% decline in PSA levels. Median overall survival was 7.3 months (interquartile range (IQR): 4.7-9.9 months). Median progression-free survival was 3.3 months (IQR: 2.5-7.0 months). Improvement in quality of life measures was noted after three cycles of therapy. Grade 3 and 4 toxicities were: neutropenia 8%, febrile neutropenia 4%, infection 2%, anaemia 3%, lethargy 1% and somnolescence 1%. One patient died as a result of neutropenic sepsis. CONCLUSION: In a poor prognostic cohort of patients paclitaxel and vinorelbine is a tolerable regimen, with a 20% PSA and objective response rate. The majority of patients achieved PSA stability. Furthermore, quality of life parameters, such as pain, were improved. However, the low level of activity of this regimen precludes its further testing.
dc.formatapplication/pdf
dc.languageEnglish
dc.publisherWILEY-BLACKWELL PUBLISHING, INC
dc.subjectChemotherapy; Health not elsewhere classified
dc.titlePhase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting
dc.typeJournal Article
dc.identifier.doi10.1111/j.1445-5994.2009.01987.x
melbourne.peerreviewPeer Reviewed
melbourne.affiliationThe University of Melbourne
melbourne.affiliation.departmentMedicine - Royal Melbourne And Western Hospitals
melbourne.source.titleINTERNAL MEDICINE JOURNAL
melbourne.source.volume40
melbourne.source.issue3
melbourne.source.pages201-208
dc.research.codefor111205
dc.research.codeseo2008929999
melbourne.publicationid146135
melbourne.elementsid323500
melbourne.contributor.authorLe, Brian
melbourne.contributor.authorRogers, Margaret
melbourne.contributor.authorBELL, RICHARD
dc.identifier.eissn1445-5994
melbourne.conference.locationAustralia
melbourne.accessrightsThis item is currently not available from this repository


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record